Kynam Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Kynam Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$176M	Hold	8,050,959	–	–	9.73%	2
2026 Q1	$188M	Hold	8,050,959	–	–	11.6%	1
2025 Q4	$169M	Sell	8,050,959 -469,041	-6%	-$8.18M	10.81%	3
2025 Q3	$131M	Hold	8,520,000	–	–	9.76%	2
2025 Q2	$79.8M	Hold	8,520,000	–	–	8.59%	4
2025 Q1	$105M	Hold	8,520,000	–	–	8.79%	4
2024 Q4	$113M	Buy	8,520,000 +2,677,075	+46%	+$45.8M	6.66%	5
2024 Q3	$112M	Buy	5,842,925 +120,868	+2%	+$2.5M	8.62%	4
2024 Q2	$117M	Buy	5,722,057 +62,057	+1%	+$1.3M	9.06%	4
2024 Q1	$135M	Hold	5,660,000	–	–	14.1%	2
2023 Q4	$122M	Buy	5,660,000 +2,060,000	+57%	+$31.7M	13.55%	2
2023 Q3	$52.3M	Buy	3,600,000 +337,996	+10%	+$6.39M	8.55%	4
2023 Q2	$68.3M	Buy	3,262,004 +56,018	+2%	+$1.17M	9.39%	4
2023 Q1	$67.7M	Buy	3,205,986 +644,799	+25%	+$16M	8.74%	3
2022 Q4	$65.2M	Buy	2,561,187 +288,272	+13%	+$6.72M	10%	4
2022 Q3	$54.6M	Sell	2,272,915 -239,325	-10%	-$5.37M	11.51%	2
2022 Q2	$48.3M	Buy	2,512,240 +579,440	+30%	+$9.65M	12.34%	2
2022 Q1	$33.6M	Buy	1,932,800 +976,635	+102%	+$16.4M	10.9%	3
2021 Q4	$20.9M	Buy	+956,165	New	+$17.7M	11.19%	3

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Kynam Capital Management's SNDX Position: Q2 2026 in Review

Kynam Capital Management held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 8,050,959 shares worth $176M. The position accounts for 9.73% of the portfolio, ranked #2.

Kynam Capital Management first reported a position in SNDX in Q4 2021 and has held it in 19 quarters since. The position peaked at $188M in Q1 2026. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Kynam Capital Management held 8,050,959 shares of Syndax Pharmaceuticals worth $176M as of Q2 2026.
Kynam Capital Management left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
Syndax Pharmaceuticals made up 9.73% of Kynam Capital Management's portfolio in Q2 2026, its #2 holding.
Kynam Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Kynam Capital Management's Syndax Pharmaceuticals position peaked at $188M in Q1 2026.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.